Recent advances in the development and evaluation of molecular diagnostics for Ebola virus disease by Tembo, John et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iero20
Expert Review of Molecular Diagnostics
ISSN: 1473-7159 (Print) 1744-8352 (Online) Journal homepage: https://www.tandfonline.com/loi/iero20
Recent advances in the development and
evaluation of molecular diagnostics for Ebola virus
disease
John Tembo, Edgar Simulundu, Katendi Changula, Dale Handley, Matthew
Gilbert, Moses Chilufya, Danny Asogun, Rashid Ansumana, Nathan Kapata,
Francine Ntoumi, Giuseppe Ippolito, Alimuddin Zumla & Matthew Batesthe
PANDORA-ID-NET consortium
To cite this article: John Tembo, Edgar Simulundu, Katendi Changula, Dale Handley, Matthew
Gilbert, Moses Chilufya, Danny Asogun, Rashid Ansumana, Nathan Kapata, Francine Ntoumi,
Giuseppe Ippolito, Alimuddin Zumla & Matthew Batesthe PANDORA-ID-NET consortium (2019):
Recent advances in the development and evaluation of molecular diagnostics for Ebola virus
disease, Expert Review of Molecular Diagnostics, DOI: 10.1080/14737159.2019.1595592
To link to this article:  https://doi.org/10.1080/14737159.2019.1595592
Accepted author version posted online: 27
Mar 2019.













Publisher: Taylor & Francis 
Journal: Expert Review of Molecular Diagnostics 
DOI: 10.1080/14737159.2019.1595592 
Review 
Recent advances in the development and evaluation of molecular diagnostics for Ebola virus 
disease 
John Tembo1, Edgar Simulundu2, Katendi Changula2, Dale Handley3, Matthew Gilbert3, Moses 
Chilufya1, Danny Asogun4, Rashid Ansumana5, Nathan Kapata6, Francine Ntoumi7, Giuseppe Ippolito9, 
Alimuddin Zumla8,10, Matthew Bates1,3,8* and the PANDORA-ID-NET consortium 
1HerpeZ, University Teaching hospital, Lusaka, Zambia  
2University of Zambia School of Veterinary Medicine, Lusaka, Zambia 
3School of Life Sciences, University of Lincoln, Lincoln, United Kingdom 
4Lassa fever research institute, Irrua University Teaching Hospital, Nigeria 
5Mercy Hospital, University of Njala, Sierra Leone 
6Zambia National Public Health Institute, Lusaka, Zambia 
7Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of Congo  
8Centre for Clinical Microbiology, Division of Infection and Immunity, University College London 
(UCL), London, UK 
9Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy 
10National Institute of Health and Research Biomedical Research Centre, UCL Hospitals National 
Health Service Foundation Trust, London, UK 
 
*Corresponding author: Matthew Bates, Joseph Banks Laboratories, School of Life Sciences, 


























Introduction: Viruses from the family Filoviridae can cause viral haemorrhagic fevers (VHFs), 
including Ebola virus disease (EVD) and Marburg virus disease (MVD). The 2014-16 outbreak of EVD 
in West Africa resulted in 11,308 deaths, representing a case fatality rate of 39.5%. During the 
outbreak, only 60% of patients were laboratory confirmed and global health authorities have 
identified the need for accurate and readily deployable molecular diagnostics as an important 
component of the ideal response to future outbreaks, to quickly identify and isolate patients.  
Areas covered: Following the outbreak in West Africa, various molecular diagnostic assays to detect 
EVD have been developed, to detect genes, proteins/antigens and antibodies associated with the 
infection. Currently PCR based techniques and rapid diagnostic tests (RDTs) that detect antigens 
specific to EVD infections dominate but recent advances in biosensor technologies have led to novel 
approaches for the development of EVD diagnostics. This review summarises the literature and 
available performance data of currently available molecular diagnostics for ebolavirus, identifies 
knowledge gaps and maps out future priorities for research in this field. 
Expert opinion: While there is now a plethora of diagnostic tests for EVD at various stages of 
development, there is an acute need for studies to compare the clinical performance of these EVD 
diagnostics. The sporadic nature of EVD outbreaks makes this extremely challenging, demanding 
pragmatic new modalities of research funding and ethical/institutional approval, to enable 
responsive research in outbreak settings. Retrospective head-to-head diagnostic comparisons could 
also be implemented using biobanked specimens, providing this can be done safely.   
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Article highlights 
• Rapid molecular diagnostic assays for EVD are a key component of an effective outbreak 
response. 
• Molecular diagnostics for Ebolaviruses are abundant and being rapidly developed, but there 
is very little evidence to suggest which tests are clinically most accurate and appropriate. 
• Validating EVD diagnostic assays against an established gold standard is very difficult in the 
context of an ongoing outbreak. 
• Head-to-head comparison of different diagnostic tests using biobanked specimens requires 
strong international leadership and equitable collaboration. 
• Regular clinical surveillance is necessary and should be affordably embedded into existing 














Viruses from the family Filoviridae can cause viral haemorrhagic fevers (VHFs), including Ebola virus 
disease (EVD) and Marburg virus disease (MVD)[1]. There are five known Ebolavirus species, namely 
Zaire ebolavirus, Sudan ebolavirus, Taï Forest ebolavirus, Bundibugyo ebolavirus and Reston 
ebolavirus, represented by the following viruses respectively, Ebola virus (EBOV), Sudan virus 
(SUDV), Taï Forest virus (TAFV), Bundibugyo virus (BDBV) and Reston virus (RESTV)[2].  There is also 
one newly proposed ebolavirus isolated from insectivorous bats, Bombali virus (BOMV), as yet not 
known to cause human disease[3]. There is only one known marburgvirus species, Marburg 
marburgvirus, with two known viruses, Marburg virus (MARV) and Ravn virus (RAVV)[2]. There is a 
third genus within the Filoviridae called Cuevavirus that is not linked to VHF in humans. 
The EVD epidemic in West Africa originated in Guinea in late 2013 and over the course of two years 
resulted in the deaths of over 11,000 people [4], mainly in Guinea, Sierra Leone & Liberia. This 
devastating outbreak caught the health systems of the affected countries and the wider global 
health community, completely unprepared, both in terms of the immediate response and in terms of 
our broader readiness and the available infection control tools for EVD [5]. Despite Ebolavirus having 
been discovered over 4 decades ago, at the start of the West African outbreak there was no 
regulator-endorsed vaccine, diagnostic or therapeutic for this deadly infectious disease, for which 
the mean case fatality rate is 60.4% (Range 24.8%-89.5%) (data extracted from the CDC table of past 
EVD outbreaks, excluding isolated and exported cases, with addition of latest update from North 
Kivu outbreak in DRC as of 17th Dec 2018: 542 cases and 319 deaths)[6, 7]. Before the outbreak in 
West Africa, previous outbreaks had occurred exclusively in Central Africa, and had been largely 
limited to the 10s or low 100s of cases, through clinical diagnosis and isolation of suspected cases 
and their contacts, using classical epidemiological and infection control techniques. For this reason, 
ebolavirus was not considered a public health priority and global health research and programme 
funding concentrated on controlling established endemic infectious diseases such as HIV, TB and 
Malaria [8]. Furthermore, there are intrinsic challenges to studying Ebola; any laboratory research on 
live ebolavirus requires BSL-4 facilities, typically led by national government health and defence 
institutions, that have many competing priorities. Then with respect to clinical studies, prior to the 
West Africa epidemic, outbreaks have previously been contained relatively quickly, making the 
standard 6-18 month research modality of writing grant proposals and winning funding obsolete. 
The scale of the West African epidemic, which lasted for over two years, induced a swift response 
from the major research and programme funding bodies to provide more funds for both 
preparedness and research activity [8]. For this reason it was possible to initiate some clinical studies 
of potential interventions, but these were largely limited to preliminary validations, and in some 
cases occurred during the tail end of the epidemic when case numbers were very low [9]. There is a 
great need for a coordinated global response to ensure that wherever and whenever the next Ebola 
outbreak might be, research studies are planned and ready to implement within a timeframe of just 
a few weeks. 
The need for accurate diagnostic tests is at the vanguard of the response to an ebolavirus outbreak, 
as they are the first line of defence in the early days and are a pre-requisite for subsequent vaccine 
and therapeutic trials. Beginning in August 2014 and over the next year, as a direct response to the 
West African outbreak and the threat it posed to global health security, the Food and Drug 
Administration FDA in the U.S granted emergency use authorization (EUA) for 10 different molecular 
diagnostic tests for Ebola [10], comprising nine Real Time Polymerase Chain Reaction (RT-PCR) – 












Africa, giving rise to preliminary performance data including some head-to-head comparisons. In this 
review we analyse the available data on the performance of these and more recent ebolavirus 
assays. We then identify the current knowledge gaps and present our opinion on future priorities for 
diagnostic development and diagnostics research for EVD.   
2. Ebola transmission dynamics 
When considering how molecular diagnostics might be developed and used to control ebolavirus 
outbreaks we must first consider the nature of the virus and its transmission dynamics. Ebolaviruses 
are helical enveloped negative-sense RNA viruses that replicate in the cytoplasm of infected cells 
and a number of outbreaks of EVD have been associated with hunting and processing of bush 
meat[11]. Whilst epidemiological data that links index cases to contact with bats [12] (which can be 
infected experimentally [13]), extensive efforts have so far failed to isolate Ebolavirus from bats, 
although ebolavirus RNA and/or antibodies (?) have been detected in a number of bat species [14-
17]. This is in contrast to Marburg virus, which has been successfully isolated from bats [18, 19] [4]. 
In human infection early cell targets are monocytes, macrophages and dendritic cells but the cell 
tropism of ebolavirus is broad and it subsequently disseminates and infects a wide range of cell 
types including hepatocytes, adrenal cortical cells, fibroblasts and endothelial cells [20]. Ebolavirus is 
shed in a wide range of body fluids, including sweat, which could account for documented secondary 
cases reporting physical contact but not with body fluids or mucosal membranes [21]. The West 
African outbreak was largely driven by ‘super-spreaders’, with 61% of cases contracted directly from 
just 3% of cases [22] and if any human cases could produce infectious aerosols they might be from 
within this 3%, but the evidence for this is weak. There have also been isolated cases where no 
physical contact is reported, although these seem most likely due to fomites and contact with 
contaminated surfaces and are in no way conclusive of aerosol transmission. There are also several 
cases of nosocomial infection in the U.S and Spain, where all safety protocols were in place yet it has 
not been possible to identify the precise route of transmission [21]. Animal studies have 
demonstrated transmission of Ebola from pigs to macaques without direct contact [23] but the 
studies didn’t rule out transmission via contact with bodily fluids or fomites. While it may be 
theoretically possible that if a human case shed sufficient virus in the respiratory tract and the virus 
could be released in aerosols, there is no conclusive evidence proving this and most epidemiological 
evidence is strongly against the likelihood of aerosol transmission.  
Another interesting consideration from a diagnostic perspective is the existence of IgG seropositive 
asymptomatic case contacts and other healthy blood donors who have no history of severe Ebola-
like disease. A study of case contacts in Sierra Leone reported Ebola IgG seroprevalence at 11% [24]. 
In a recent study from Boende Health Zone in the DRC (site of the 2014 EVD outbreak) a range of 
serological tests were used to screen 565 health workers (not restricted to case contacts), among 
whom 234 (41.4%) were sero-reactive to at least one EBOV protein [25]. Among these cases, sera 
from a small minority (16) could neutralize a recombinant HIV virus expressing EBOV glycoprotein 
(GP). It is now widely accepted that in a minority of cases EBOV can cause a mild, sub-clinical or 
asymptomatic but replicative infection [26, 27]. Epidemiologically it is difficult to argue that this 
accounts for seroprevalence rates observed in healthy populations with no history of EVD disease or 
case-contact, data from the DRC suggest EBOV IgG seroprevalence rates of 11% among the general 
population [28] and up to 18% among Efe pigmy populations [29]. In Sierra Leone, a retrospective 
biobank study of patients with suspected Lassa virus (LASV) infection (but who were LASV IgM and 
malaria negative) found low titre Ebola IgM in 8.6% of all cases [30]. Other non-mutually exclusive 
theoretical explanations for population level seroprevalence could include the idea that the EBOV 
antigens used could be cross-reacting with antibodies from novel/unknown filovirus species that 












homologous proteins of other viruses such as the GP proteins of arenaviruses or bunyaviruses [31] 
or simply unrelated non-specific binding/noise due to issues with assay use or design and validation.  
A final consideration is the issue of long-term shedding of ebolavirus in EVD survivors. In patients 
who survive Ebola, viraemia usually becomes undetectable around 2 weeks after the report of first 
symptoms [32], although cases of persistent positive results in asymptomatic survivors have been 
documented in both pregnant women [33] and semen specimens [34-36], raising questions about 
the possibility of vertical or horizontal sexual transmission from survivors. Between March 20th 2015 
and March 16th 2016, there were 8 documented ‘flare-ups’ of EVD thought to have arisen from 
survivors infecting close contacts. In 4 of these cases, the suspected body fluid was semen, from 
men discharged from Ebola treatment units (ETUs) between 1.5-17 months previously. There is one 
well-documented case of vertical transmission, in which a 9 month old baby who died tested 
positive for EBOV by oral swab. The mother and father were IgG positive (but IgM negative) and 
tested positive for EBOV RNA in breast milk and semen respectively. Both were almost certainly 
examples of undiagnosed survivors. Sequence data confirmed the isolate from the baby was closely 
related to that detected in the breast milk, but was more distant from that detected in the semen 
[37] [34]. A study on serial samples collected across both of the 1996 EVD outbreaks in Gabon 
(caused by EBOV), demonstrated that 11/24 case contacts (with known exposure to infected 
materials from fatal and non-fatal cases) developed Ebola-specific IgM and IgG responses at 23 days 
post exposure. The paper also presents nested PCR results for two of these sero-converting 
asymptomatic cases, showing positive detection of Ebola virus RNA (confirmed by sequencing of the 
298bp fragment), waning by day 19 and day 23 respectively, suggestive of replicative but 
asymptomatic infection, although the paper does not mention any effort to culture virus. [38]. There 
is a need to explore this idea further during contemporary outbreaks, using the latest molecular 
tools. A better fundamental understanding of the prevalence, virology and immunology of such 
cases might inform on diagnostic or vaccine design, to the operational aspects of using molecular 
diagnostics in EVD control.  
 
3. Molecular diagnostics for Ebola virus disease 
Diagnostic assays based on the detection of Ebola-specific antibodies are of limited use in the 
diagnosis and management of EVD because the immune response to primary infection only becomes 
detectable around three weeks post-exposure [38] and a significant minority of the healthy 
population are IgG seropositive [39]. For this reason most of the efforts to develop molecular 
diagnostic tests have focussed on the detection of either antigenic proteins or nucleic acid (Tables 1 
& 2). We drew up tables using information from diverse sources including published articles, 
government agency reports, product inserts and manuals and through direct contact with 
companies or through their websites. There are at least 18 companies or organizations with 
Ebolavirus RT-PCR assays at various stages of development (Table 1), and a further 9 companies 
developing antigen-based rapid diagnostic tests (RDTs) (Table 2). The over-arching vision of how 
these different diagnostic technologies might be employed is that the much cheaper and easier to 
use RDTs, which should not require cold-chain reagents, would be used as a ‘rule out’ (high 
sensitivity, but with possibly lower specificity) triage tool at community health posts and by contact 
tracing teams, requiring no laboratory infrastructure and implementable by large numbers of 
relatively low-skilled personnel. Patients who flag positive would then be referred to larger health 
centres with laboratory and PCR facilities. For confirmatory testing WHO recommends RT-qPCR tests 
[40] that are generally perceived to be more specific than RDTs [41]. During the first 3 days after 












RT-qPCR assays typically require cold-chain reagents and take 1-3hrs, depending on throughput and 
batching, but in real world settings reporting times are often several days [43] and factors like 
specimen transport, human resources and supply chain are more important causes of delay than 
hands-on analysis time [44]. The requirement of intravenous blood is a risk for healthcare worker 
transmission, compared with taking oral swabs or other non-invasive specimens [45]. A 
retrospective modelling study suggested that using dual screening with both a highly sensitive RDT, 
followed by a highly specific PCR assay, could have reduced the epidemic in Sierra Leone by up to a 
third [43]. However, there may be as yet unknown filovirus species that may not be detected by the 
current molecular diagnostics, as occurred with the first outbreak of BDBV, where nucleotide 
difference between BDBV and TAFV (its closest relative) was 32%[46]. It must be noted here that this 
was not the case for the newly discovered BOMV[3]. 
 
Before the ebolavirus outbreak in West Africa, both EVD outbreak response & research in selected 
BSL-4 facilities relied on in-house RT-PCR and RT-qPCR assays, so the rapid proliferation of 
competing commercial molecular diagnostics for EVD is welcomed, with many companies adapting 
the platforms and chemistries they have developed for other infectious disease assays [47, 48]. 
However, this rapid increase in the quantity of novel diagnostics means we have to choose which 
one/s to use and provide evidence for that decision. Classically, any novel diagnostic test should be 
evaluated on genuine clinical specimens (prospectively collected or biobanked) against an 
established gold standard. For Ebola, this poses three challenges: 1) The established gold standard is 
culture (followed by electron microscopy, histological and molecular analysis), requiring BSL-4 
facilities, which is impractical in outbreak settings, 2) Ebola outbreaks are sporadic, and so there is 
no steady supply of patients on which to conduct clinical diagnostic trials and 3) Biobanked 
specimens are finite and their use in diagnostic evaluations is a significant public health risk unless 
conducted in a BSL-4 facility. For these reasons, there have been very few head-to-head 
comparisons of different diagnostic tests. For all diagnostics in which the RNA extraction step is not 
integrated into a self-contained cartridge [47, 48], the RNA extraction protocol used [49] and the 
specimen type tested [50] present additional sources of variation, which might impact diagnostic 
test accuracy. A validation study undertaken in 2004 (thus not including many of the newer assays) 
found that the impact of RNA extraction kit was minimal, but that results varied significantly 
between the 24 laboratories involved in the study. Whilst 78.6% of labs were able to detect 
ebolavirus at 2.2x105 copies/ml, only 46% of labs were able to detect the virus at concentrations 
lower than 104 copies/ml [49]. A more recent study sent out 11 standards (10-fold serial dilutions of 
heat inactivated tissu  culture supernatants) to 83 different laboratories (including 21 labs from 
Sierra Leone and Guinea), who returned 106 datasets (some labs used multiple assays). The 10-4 
dilution was detected in 89.6% (95/106) of datasets, whereas the 10-5 dilution was detected in just 
79.2% (84/106) of datasets [51]. Another striking finding is that for any given dilution, the range of Ct 
values is highly variable, with the interquartile range spanning from about 5 cycles (at titres of 10-3 
and above) up to 10 cycles or more for lower dilutions. Unfortunately the viral genome copies of 
these standards are not reported, which makes it difficult to correlate these results with known 
detection limits in clinical specimens. The most commonly used assays by far were the kits produced 
by Altona Diagnostics (Table 1), accounting for 44% (47/106) of datasets overall and 85% (47/55) of 
commercial assays used. For this reason it makes sense that we first look at the available data on the 
performance of these assays and their use during the West Africa epidemic (section 3.1). The 
available data on other assays is severely limited, but in this review we shall also dedicate a section 












assay is the primary assay being using in the current EVD outbreak in the Democratic Republic of 
Congo (at time of writing: Mar 2019). 
 
3.1 Altona Diagnostics RT-qPCR assays 
Altona Diagnostics (Germany) initially developed two different ebolavirus diagnostics kits, the 
‘RealStar® Filovirus Type RT-PCR Kit 1.0’, which can differentiate between all 5 known ebolavirus 
species and marburg virus, and the ‘RealStar® Filovirus Screen RT-PCR Kit 1.0’, which can detect 
either ebolavirus or marburgvirus, but cannot differentiate between ebolavirus species. This latter 
‘Screen’ assay is the one that has been most used in West Africa. Subsequently Altona Diagnostics 
have developed a third assay, the RealStar® Zaire Ebolavirus RT-PCR kit 1.0’, which has been designed 
to specifically target EBOV, which was the causal agent of both the West African epidemic and the 
four concurrent/subsequent outbreaks in the DRC. Non-multiplex assays tend towards greater 
sensitivity and improved signal-to-noise ratios at low viral RNA concentrations [42]. The ‘Screen’ 
assay has a 95% LOD of 500-1500 copies/ml, whereas the ‘Type’ assay was shown in one study to 
have a 95% LOD of 6250 copies/ml (Table 1). The ‘Zaire’ assay is currently registered for Research 
Use Only (RUO) and at the time of going to print, Altona Diagnostics had not released any LOD data. 
Evaluation of capillary blood (a safer and more convenient finger prick blood collection option) 
showed that yields were lower than using venous blood, though this finding has been criticised as 
the authors did not correct for blood volume, although they argue overall viral concentration in 
blood is the same whether obtained from the vein or capillary [45]. All Altona assays can be used 
with multiple RNA-extraction and Real Time PCR platforms (Table 1). A large observational study in 
Guinea using the ‘Screen’ assay showed that higher viral loads (as approximated by Cq values) are 
associated with higher case fatality ratios [52]. The same study showed that mortality was highest in 
young children >5years of age, and those aged >45yrs, while among children aged 5-14 years, 
malaria parasitaemia was associated with increased risk of mortality [52]. By contrast, in another 
study that also included adults and children, higher levels of malaria parasitaemia were found to be 
linked with a reduced risk of mortality [53]. 
The RealStar® ‘Screen’ assay has been used as the ‘Gold Standard’ in several validation studies, but 
studies comparing multiple Ebola diagnostic tests in parallel have demonstrated significant levels of 
discrepancy between different tests [54]. In this Lancet study a total of 277 biobanked EDTA whole 
blood samples were re-tested with the RealStar® ‘Screen’ assay and the Corgenix ReEBOV Antigen 
Rapid test kit. Their analysis showed that where samples were previously shown to be positive by 
these two different tests, subsequent re-analysis by RT-PCR was highly reproducible, using both the 
Altona and Trombley assays (an in-house assay developed by the U.S military [55]). However, among 
16 samples that were previously discordant (RDT +ve, Altona –ve), the Trombley assay identified 6 
positives, one of which was now also positive by Altona. Similarly, among a set of 18 samples that 
were initially concordant negatives (RDT-ve, Altona-ve), there were now 3 positives with the 
Trombley assay [54]. These findings illustrate that classic molecular diagnostic developer’s 
conundrum; no two assays ever perform exactly the same. These results point towards an improved 
sensitivity for the in-house Trombley assay, compared with the Altona assay, and indeed during the 
West Africa outbreak, the PHE mobile lab in Freetown switched from using the Altona assay to the 
Trombley assay due to ‘performance issues’ [56]. Similarly, other evaluations have identified 
probable false negatives using the RealStar® Screen assay [57, 58]. However, these results are 
preliminary and often based on opportunistic data collected during outbreak response, as opposed 













3.2 Xpert® Ebola 
The GeneXpert platform developed by Cepheid (Sunnyvale, CA) is a cartridge-based close-to-point-
of-care Real Time PCR machine. In the global health sector the platform is primarily known for the 
Xpert MTB/RIF assay, which is WHO-endorsed and is being rolled out across several countries for 
routine TB care, although the operational effectiveness of the assay in different settings and patient 
groups is still much debated [59]. Given that the GeneXpert platform is now widely available and 
because Cepheid’s Ebola assay is currently being used in the present DRC outbreak, we chose to 
review the assay and all available data. In March 2015 the ‘Xpert® Ebola’ assay was granted 
‘emergency use authorization’ (EUA) [60] and the assay was used by some labs during the West 
Africa outbreak [61-63]. The company are one of the few to publish a ‘list-price’ with each cartridge 
priced at $19.80 and the 4-channel GeneXpert machine costing around $20,000 (inclusive of low and 
middle income country (LMIC) discount). The assay targets two ebolavirus genes, that encode the 
nucleoprotein (NP) and glycoprotein (GP), contains internal controls and is interpreted 
automatically, minimizing operator bias in reporting results. Unlike many PCR-based assays, the 
cartridges and lysis buffer can be shipped at 2-8oC, so do not require freezer storage. The self-
contained cartridges allow samples to be processed independently of each other (without batching) 
and offer a high degree of containment and biosafety, as the first step involves addition of the 
sample to 2.5ml lysis buffer containing 4.5M guanidinium thiocyanate [32], which inactivates the 
virus disrupting the capsid and lipid envelope releasing the DNA during a 10-20 minute incubation at 
room temperature. The specimen is then added to the reaction cartridge, which is sealed for the 
duration of the analysis and can be discarded and incinerated after use. The Xpert® Ebola assay is 
most sensitive at detecting the NP gene, with median cycle thresholds being roughly 5 Cq values 
lower for NP than for GP [62, 64]. The software scores a discrepant result as ‘indeterminate’, 
requiring repeat testing and preliminary data suggests the Xpert® Ebola assay is up to a log more 
sensitive than the Altona assays [32](Table 1), but the only way to confirm differences in analytical 
sensitivity between two diagnostic assays is through head-to-head comparison. A comparison 
between the Xpert® Ebola assay and the in-house Panning ebola assay [65] did not demonstrate any 
significant difference in analytical sensitivity, with both assays demonstrating an LOD of 163 RNA 
copies/ml (equivalent to 1 TCID50/ml) [66]. A clinical validation study comparing the performance of 
the Xpert® Ebola assay with the in-house Trombley Zaire EBOV nucleoprotein assay, which does not 
perform as well as the Zaire EBOV glycoprotein assay, found  the Xpert® Ebola assay to be positive in 
eight specimens that were negative by the Trombley Zaire EBOV nucleoprotein assay [62]. Seven of 
these 8 cases were all recovering convalescent patients, consistent with another study where the 
Xpert® Ebola assay was more sensitive than an in-house Trombley assay at detecting virus in 
convalescent patients [63]. 
Ebolavirus can persist and be isolated from semen for up to several months after infection [34, 67], 
although documented evidence of transmission from semen is rare. This may be due to ostracizing 
of Ebola survivors leading to less sexual activity and hence exposure of contacts to seminal fluid or it 
may suggest the risk of transmission from semen for convalescent patients is far lower than the risk 
of transmission from those who are acutely ill. Spiking studies have evaluated the Xpert® Ebola 
assay’s performance in semen, which initially flagged internal control failures [64], but this was 
overcome by reducing the sample volume and addition of dithiothreitol (DTT) to stabilize the RNA-
dependent DNA polymerase. Conversely, another spiking study (using inactivated Ebola virus) did 
not report any indeterminate results, and determined LODs of 1000 copies/ml and 275 copies/ml for 
semen and whole blood, respectively [68].  
 












In addition to Altona Diagnostics and Cepheid, there are at least an additional eleven companies or 
institutions that have developed RT-qPCR assays for Ebola (Table 1). For many of these assays, one is 
reduced to quoting the companies’ internal data on assay performance, gleaned from company 
websites, product manuals and regulatory documentation. The analytical sensitivity of multiple 
assays has rarely been independently compared in parallel, controlling for the many sources of 
variation that exist (standards used, specimen type, thermocycling and RNA extraction 
platforms/protocols etc.). The most comprehensive study to date compared 6 different commercial 
assays (RealStar® Filovirus Screen, RealStar® Filovirus Type (Altona Diagnostics), FTD® Ebola 
(FastTrack Diagnostics), LightMix Ebola Zaire rRT (Roche), Lifetech Ebola Virus (Zaire 2014) & Lifetech 
Lyophilized Ebola Virus (Zaire 2014))(Life Technologies), representing those available in Switzerland 
at the time (and 5 in-house assays) [44]. The assays were comparing using in vitro transcripts (IVTs) 
of both the L and NP genes, derived from the sequences of two clinical isolates of Ebola from the 
West Africa outbreak. In this analysis, the two Altona Diagnostics assays had the highest and joint-
second highest LOD as measured by copies/ml (6250 copies/ml and 1250 copies/ml)(Table 1) [44], 
hence the rationale for the development of the new EBOV-specific assay [69]. The top-performing 
assay was the Lyophilized Lifetech assay, with an LOD of just 62.5 copies/ml. This assay also had the 
shortest thermocyling time (50 minutes) and total turnaround time (105-130 minutes) and was the 
only assay that could be shipped/stored at 2-8oC (as opposed to -20oC).  
 
Outside of this one study, it is extremely difficult to make meaningful comparisons in terms of 
analytical sensitivity between different diagnostic tests. LOD data are reported using different units 
(RNA copies/ml, RNA copies/test, PFU/ml, PFU/test or TCID50/ml), and standards are constructed 
using different templates (live virus, inactivated virus, extracted genomic RNA or IVTs) and different 
matrices (distilled water, tissue culture supernatant, blood, semen and urine). These factors can 
influence assay performance by multiple orders of magnitude [42, 70]. With all the new assays 
available, we really have insufficient independent analytical sensitivity data on which to make a 
rational choice as to which assays should be prioritised for clinical diagnostic evaluation. Just 4 of the 
available assays are fully integrated with dedicated platforms (Xpert® Ebola assay, Idylla™ prototype 
Ebola virus test and the two FilmArray assays). In addition, Altona Diagnostics have collaborated 
with Alere and academic partners to develop a close-to-point-of-care assay using Alere’s cartridge-
based Alere q system. Fully integrated diagnostic assays have several key advantages, the most 
important being their possible use by relatively low-skilled health workers at distant field sites close 
to epidemiological foci of transmission. However, there is also an argument to be made for ‘open’ 
assays that are not tied to specific diagnostic platforms. This flexibility allows different labs and 
national outbreak response programmes to exploit existing infrastructure without the requirement 
for expensive new ‘lock-in’ platforms, ensuring the benefits of a free-market in diagnostics are 
maximised, making it easier for policy and practice to keep pace with the development of new 
diagnostic assays [71].  
 
Looking at other characteristics as laid out in Table 1, all but 4 of the available commercial assays, 
are targeted specifically to EBOV (Table 1). This focus on EBOV is understandable, as the five recent 
outbreaks (four in DRC (2014, 2017 & 2018a, 2018b), and one in West Africa (2014)) were all caused 
by EBOV. However, the three previous outbreaks to these were all alternative filoviruses; in 2011/12 
Uganda had three separate outbreaks of SUDV and the DRC had one outbreak of BDBV. 
Furthermore, prior to the West Africa epidemic of EBOV, the largest filovirus outbreak was the 
Uganda outbreak of 2000 & 2001, in which there were 425 cases with 224 (53%) mortalities caused 
by SUDV (although this has now been surpassed by the 2018b EBOV outbreak in DRC). There are 
currently only four commercial assays that can detect SUDV; the two original Altona assays (Screen 
& Type), the Idylla™ prototype Ebola virus test (Biocartis (Mechlen, Belgium) & Janssen 
Diagnostics)[72], which uses a fully integrated system along the lines of the GeneXpert, and OM-












outbreak (2018b) in the DRC is employing mainly the Xpert Ebola assay [74], due to its potential ease 
of use in field clinic settings and strong safety profile. In a future outbreak with a non-EBOV species, 
we would be reliant on the Altona ‘Screen’ assay and previously developed in-house assays 
developed by government special pathogens units (Table 1). Furthermore, the focus by diagnostics 
developers on EBOV maybe shifts the balance of probabilities; looking ahead our capacity to quickly 
identify and respond to EBOV outbreaks might become quite good, whereas for the other filoviruses, 
we might be less well prepared, and hence outbreaks caused by rarer or novel filovirus species may 
have a higher risk of expansion. The latest genomic surveillance is identifying novel filoviruses such 
as Bombali virus (BOMV) (recently discovered in free-tailed bats in Sierra Leone [3] and Lloviu virus 
(LLOV) (from Spain [75]). An rVSV BOMV-GP-expressing recombinant pseudovirus was shown to be 
able to enter permissive cells via the common filovirus receptor (NPC1) but this does not prove 
pathogenicity in humans. Without any prior evidence of pathogenic infection in humans, the balance 
of probabilities is weighted against a pathogenic role for such novel animal viruses in humans. As 
new human pathogens are always emerging ‘Disease X’ has now been added to the WHO blueprint 
of priority diseases [76]. An example of ‘Disease X’ might be something like Lujo virus (LUJV) 
haemorrhagic fever [77]. This novel Arenavirus (the same family as Lassa fever) discove ed in Zambia 
& South Africa in 2008, killed 4/5 people infected, including three healthcare workers. Our 
preparedness for future outbreaks must not be blinkered, but must be adaptable, with investments 
in infrastructure and training having provision for identifying novel pathogens and rapidly developing 
effective diagnostic assays. 
 
Continued analysis of assays in Table 1 shows that the majority of ebolavirus RT-qPCR assays (both 
commercial and in-house) use TaqMan probes. Most of them can in theory be performed using 
multiple thermocycling platforms, although have often only been validated on one or two machines. 
Likewise, most assays do not have integrated RNA-extraction and so this must be factored in when 
considering assay performance and the economics of providing laboratory diagnostic services for 
EVD. Just three RT-PCR assays employ LAMP (loop mediated isothermal amplification) chemistry that 
is often touted as appropriate for use in low-infrastructure environments, but you still need 
electricity and a -20oC cold-chain, plus the assays can only be run at established labs by trained 
biomedical scientists. Only one of the three assays is commercially available; the Benzine - RT-LAMP 
assay [78](Lucigen Corp). Another characteristic that is often overstated in promotional literature for 
commercial diagnostic tests for Ebola is turnaround time. Whilst a shorter turnaround time is always 
preferable, differences of 1-2hrs are probably not going to be the rate-limiting step in the logistics 
chain from clinical evaluation through to initiation of appropriate treatment/care, where the 
availability of healthcare personnel and logistics for sample transport are more likely to be rate-
limiting. Effective laboratory diagnostic preparedness for EVD should be anchored in a competent 
and well-resourced national reference laboratory (that is centrally funded through a national 
university or government research institute, with active research and training programmes on 
emerging infectious diseases), which can support a range of assays and can adapt and introduce new 
assays as appropriate. Whilst the situation might vary depending on the specific geopolitics of the 
country involved, we feel that for many countries, in the early days of an outbreak response, all 
specimens should be transported to and processed in this centralized facility. It is only if these initial 
control efforts fail, that there is really a need for disseminated laboratory diagnostic capacity [79]. 
The main thrust of preparedness for emerging infections should be to establish surveillance systems 
and response capacity so that vast deployments of field diagnostics are not required.  
 
 
3.4 Rapid Diagnostic Tests (RDTs) 
Table 2 details the descriptive characteristics of nine rapid diagnostic tests (RDTs) for EVD that are 












community health volunteers in the field and that they should be highly sensitive ‘rule-out’ tests, to 
triage patients to larger evaluation units for confirmatory testing [41]. But obviously the greater the 
specificity you can achieve with such tests the better, as each false positive case will be referred to 
an ebola treatment centre, putting them at high risk of contact with genuine cases. Even if infection 
control at the treatment centre is working extremely well, the fallout from low specificity being 
reported in lay media could be detrimental. If people think they are going to be incorrectly 
diagnosed with ebola it will deter them from seeking care, and fuel suspicion of the public health 
system [80, 81].  
 
Some of these issues are nicely illustrated by efforts to evaluate the performance of the ReEBOV 
Antigen Rapid test (Zalgen Labs LLC). The PHE-lab in Port Loko, Sierra Leone, published a field 
validation study in 2015 [54], comparing the performance of the ReEBOV assay against the RealStar® 
Filovirus Screen RT-PCR Kit 1.0 (Altona Diagnostics). The ReEBOV assay appeared to out-perform the 
Altona assay, despite the latter having an established LOD over 1000 times lower than the RDT. For 
operational reasons the study team ran the Altona assay on a platform (SmartCycler II) that the 
manufacturer knew would give a significantly higher (30-fold) LOD, resulting in the clinical diagnostic 
sensitivity of the ReEBOV RDT being exaggerated (100%)[82, 83]. Other validation studies delivered 
sensitivities of 62% [84, 85] and 91.8% [86], highlighting the challenges of evaluating RDTs in the 
absence of well-defined gold-standards. EUA for ReEBOV was revoked by FDA on 18th May 2018 
following request by the manufacturer, Zalgen Labs [87].  
 
The Ebola eZYSCREEN lateral flow assay developed by BioMérieux and academic partners in France, 
achieved a very high level of specificity (98.9%), but a much lower sensitivity (65.3% on whole blood, 
74.5% on sera). This clinical validation was undertaken in Guinea during the end of the West African 
epidemic using the RealStar® ‘Type’ assay as gold-standard. The Cq values from the Altona assay did 
not differ between true positives and false negatives, suggesting there could be some factor 
independent of viral load that might be affecting the performance of the eZYSCREEN assay. An 
evaluation of the OraQuick RDT on blood detected only 5/7 PCR positives and 8 PCR-negative 
specimens were ‘false’ positive by RDT [88]. The EVD RDTs that have been developed appear to have 
consistently lower accuracy than RT-qPCR  [89], and their use and potential role needs to be 
carefully considered. It is contingent on key factors, such as the temporal point within an outbreak, 
the number of suspected Ebola patients being tested and the real prevalence of Ebola within those 
who are being tested. Operational studies highlight the need for training, even on simple RDTs with 
relatively straight forward read-outs and for simple algorithms combining RDT and PCR results [54, 
88]. Training needs to be repeated regularly to maintain preparedness, with high staff turnover in 
the medical sector, whilst during an outbreak there might be the need to expand diagnostic services 
to additional new locations. Another consideration is the potential of POC RDTs to find their way 
onto the market, where they might be used in the absence of a healthcare professional to ensure 
the test is done correctly, and to interpret the result [79, 90]. One LAMP-PCR-based assay has 
conjugated Ebola-specific probes to hCG, so that the assay can be read using an off-the-shelf 
pregnancy test [91]. 
 
3.5 Metagenomic sequencing based diagnostics 
 
As we mentioned earlier it is important to have diagnostic tools that are able to identify novel 
pathogens and be able to study the molecular epidemiology of strains in current outbreaks. Next-
generation sequencing (NGS) technology has been used to great effect as a surveillance research 
tool during and after the West African epidemic[92], to shed new light on our understanding of the 
molecular epidemiology of the ebolavirus during outbreaks [93], giving a fascinatingly detailed 












arising from persistent viral shedding in survivors [34]. Whole genome sequence (WGS) data has also 
been used to look at mutations in specific genes that might be associated with virulence or tropism, 
such as mutations in known b-cell epitopes or cell-binding domains of the ebolavirus GP [95]. 
Comparative analysis shows that VP24, 30 and 40 are relatively conserved, whereas the GP and L 
genes show much higher uptake of non-synonymous mutations [96]. Whilst the mutation rate in the 
West Africa epidemic (1.23 x 103 sub/site/yr) was in line with that observed in previous outbreaks 
[96-98], the sheer size and scale of the epidemic represents a previously unparalleled number of 
concurrent replicative passages in human hosts, leading to a sharper increase in genetic diversity 
than seen in previous outbreaks [98]. WGS data is also of use to diagnostic developers, who can 
monitor for the emergence of mutations that might affect assay performance [99].  
 
Whilst NGS should continue to be included as an integral component of surveillance efforts [100], it 
is also increasingly being considered as a possible diagnostic tool for infectious diseases to detect 
mutations linked with drug resistance and to monitor antiviral therapy [101, 102]. The expensive 
platforms and cold-chain reagents required for NGS have largely precluded their use as front-line 
diagnostic tools in LMICs, but the emergence of nanopore sequencers (Oxford Nanopore) has 
changed this and an increasing number of research groups are using them to develop diagnostic 
tools for both viral [103] and bacterial infections [104]. MinION nanopore sequencers were piloted 
during the West Africa epidemic, using a targeted approach, where viral nucleic acids are enriched 
by targeted RT-PCR, to ensure sufficient read depth and overcome host background [105]. Nanopore 
sequencing technology originally required a DNA library, but there has been rampant innovation and 
the platform now supports direct sequencing of RNA libraries [106]. Furthermore, others have also 
developed enrichment strategies to aid detection of ebolavirus and other emerging pathogens [107, 
108], but the real power of nanopore sequencers in the field, however, is the potential to identify 
novel viral pathogens at source, without the need to ship-specimens overseas. Clinical specimens 
such as sera, urine or saliva, can be filtered to isolate virus particles. Nuclease treatment then 
degrades background host DNA, whilst viral nucleic acid remains protected within the viral particle. 
Subsequent nucleic acid extraction allows sequencing of the extracellular ‘virome’ of the clinical 
specimen of interest [109]. Although not in a diagnostic context, Filoviruses have been effectively 
concentrated using mini hemopurifiers [110], although translating this ‘concentrating’ approach to 
the diagnostic context might raise additional biosafety concerns. Currently, these are still very much 
research tools, requiring considerable wet-lab and bioinformatics expertise and so after the 
discovery of a novel etiological agent, one would then want to rapidly design an RT-qPCR or antigen-
based assay to detect the target of interest.  
3.6 Novel biosensor approaches 
The age of PCR will probably pass to make way for the new generation of highly sensitive and 
specific biosensor-based diagnostics that are emerging, using the latest microfluidics and 
nanotechnology. Recent advances in biosensor technology have led to the production of possible 
cheap Ebola diagnostics and miniaturisation of these techniques makes it possible to diagnose 
multiple pathogens on a single chip. One strategy involves magnetic particle-based biosensors [111], 
where pathogen-specific antibodies, antigens or DNA are conjugated to a magnetic bead, to allow 
high levels of enrichment for the target of interest. Capillary electrophoresis systems can be 
engineered to create lab-on-chip microfluidic devices that can efficiently separate and then detect 
target nucleic acid at down to picomolar concentrations [112]. Peptide nucleic acid probes (PNAs) 
contain a polyamide backbone that mimics the pentose-phosphodiester backbone of DNA [113]. This 
makes them more stable and allows them to bind target sequence more tightly. Immuno-PCR (iPCR) 
is an ELISA-like technique, where the secondary antibody is covalently bound to a DNA target that 












(SPR) and photonic crystal-based label-free immunosensors are other possible approaches that have 
been recently described elsewhere [113, 114].  
 
These novel biosensor technologies are at an early stage of their development and a detailed 
technical review is beyond the scope of this article, but we thought it would be interesting to 
highlight one of these technologies, which illustrates a novel approach that might be applicable to 
filoviruses or other emerging pathogens. Single Particle Interferometric Reflectance Imaging Sensor 
(SP-IRIS) is potentially a rapid and sensitive diagnostic technique that potentially needs minimal 
sample preparation or user expertise and can be used to test for multiple pathogens simultaneously. 
SP-IRIS technology is essentially an enhanced form of light microscopy that allows you to visualise 
(and hence count) individual virus particles [115]. Virus-specific monoclonal antibodies are 
conjugated to DNA, which hybridizes with a DNA-spotted sensor surface. The hybridized DNA forms 
a stem that raises the height of the antibody above the sensor surface, overcoming some of the 
short-comings of immobilizing antibodies directly to sensor surfaces, where steric hindrance through 
multiple contacts with the surface or with neighbouring antibodies are known to impair antibody-
antigen binding. The sensor chip is visualized with an NVDX10 reader (nanoView Diagnostics) that 
illuminates the sensor chip at specific wavelengths using an LED light source. This bench-top 
machine contains a 40X 0.75NA objective and a high spec CMOS (complementary metal-oxide 
semiconductor) digital camera. A computer then applies a complex algorithm based on averaging 
multiple images, to construct a composite image and also count the number of virus particles. One 
chip can be printed with different arrays of DNA-probes to bind mAbs specific for different viruses 
simultaneously [116]. This DNA-tethering technology increases the sensitivity of the sensor by 6-fold, 
allowing resolution of individual virus particles. The DNA-printed sensors are resistant to the high 
temperatures often used in the manufacture of microfluidic POC diagnostic devices and are cheaper 
to manufacture than antibody-printed sensors [115]. This technology has been successfully piloted 
to visualise both Ebola virus [117, 118] and Zika virus [116] particles. It’s conceivable that such a 
technology could be optimized and developed into a diagnostic tool that is sensitive, specific, rapid 
and multiplexed.  
3.7 microRNA as biomarkers 
microRNAs (miRNAs) are non-coding nucleotide sequences that function to regulate 
posttranslational expression of target genes  [119]. miRNAs are highly stable in biological fluids and 
can withstand many freeze-thaw cycles and have been used in cancer diagnosis as well as in the 
diagnosis of some infectious diseases[120]. They can be used as biomarkers for EVD[121]. Several 
miRNAs have been predicted for EBOV [119, 121-123].  Three miRNAs have been shown to be most 
abundant and can be detected before symptoms of EVD begin[124], showing promise for early 
diagnosis of EVD. Translating these results into a viable diagnostic test is a challenge. There are 
several things that determine the viability of an assay; the biological sample used, its mode of 
collection, the method of RNA extraction and the detection method used[120]. 
4. Conclusions 
Molecular diagnostics have a key role to play in the control of EVD and other infectious disease 
outbreaks with pandemic potential. The West Africa epidemic has stimulated a lot of activity, with 
development or commercialization of previously designed in-house assays, collaborations between 
commercial partners with complementary intellectual property (marrying ‘assay’ with ‘platform’) 
and the creation of completely new diagnostic products by commercial entities, often adapting 
chemistry or platforms they have previously developed for other infectious disease threats. There is 
a range of exciting new biosensor technologies being developed for EVD and other emerging 
infections, and there is a need to obtain some preliminary validation of these techniques on clinical 












metagenomic sequencing was piloted during the West Africa outbreak. However, metagenomic 
approaches are currently best-suited to answering research questions with respect to epidemiology 
and genomics, or index case pathogen ID and local capacity should be developed through the 
incorporation of sequencing and pathogen ID into surveillance and training efforts. We are not close 
to any kind of end-user sequencing-based diagnostic device, comparable with the close-to-POC 
devices like the GeneXpert or Alere q [79]. There is a dearth of quality studies comparing the 
analytical and clinical accuracy of these new tests and this can only be addressed through 
collaborative endeavour and the sharing of resources, such as biobanks. The dual testing approach 
(triage-confirm), which makes a lot of sense for chronic infectious diseases, particularly TB, is 
possibly overly cumbersome for EVD outbreaks, where rapid and accurate diagnosis is paramount to 
stem transmission. The nature of EVD, characterised by very large viral loads in blood, means that 
both antigen-detection RDTs and field-use PCR platforms could be optimized to sufficient accuracy 
for outbreak control, providing they are deployed promptly. Key to this is the need for ongoing 
clinical surveillance, supplemented by reasonably frequent (monthly-quarterly) deployment of 
national disease control laboratory teams with VHF assays. Such activities could be readily 
embedded into ongoing national health programmes, such as those for TB, HIV or Malaria, at 
minimal additional cost. 
4.1 Expert opinion 
Developing appropriate and effective EVD molecular diagnostics for close-to-point-of-care use in 
resource-limited settings is challenging. Even for established endemic infectious diseases, such as 
tuberculosis (TB), there are relatively few WHO/FDA approved molecular diagnostic tests. These 
approvals are supported by large bodies of evidence (Pubmed lists 34 clinical trials on Xpert 
MTB/RIF, although there is still much debate about how the assay might be best utilized), comprising 
initial validation studies, through to full-blown clinical trials, including head-to-head trials and more 
complex trials comparing different diagnostic algorithms and other operational studies. The physical 
fragility of most thermocycling platforms presents fundamental limitations for their deployment to 
field clinics, although currently PCR-based assays are inherently more specific than serology-based 
RDTs. All molecular diagnostic tests for use in LMIC field settings have to be sufficiently sensitive and 
specific, must be robust and easy to implement with minimal cold-chain or electricity requirements, 
and they must be affordable. For EVD there are two additional challenges; 1) the sporadic nature of 
the outbreaks means there is not an endemic patient population in which to readily evaluate new 
diagnostic tests and 2) Ebola virus is a BSL-4 pathogen, which adds considerable complexity to 
designing diagnostic clinical trials during active outbreaks, in particular, ethical questions of 
acceptable safety levels for those implementing the trial and concerns for the patients for whom the 
priority is clinical care. Knowing which of the available diagnostic tests is most accurate could 
potentially have a big impact on our ability to control outbreaks. The diagnostic response to the 
current outbreak in the DRC (and other recent outbreaks) utilizes RT-qPCR assays, but the available 
analytical sensitivity and specificity data has been generated using a range of different 
methodologies making comparisons very difficult. There is a need for head-to-head comparisons 
using available biobanks to definitively determine those which are most accurate, ideally 
incorporating available clinical and epidemiological data. With respect to RDTs, there is even less 
data available, making any kind of meaningful comparison based on published data impossible.  
There is a need for coordinated action to evaluate the available diagnostic tools using available 
biobanks and to incorporate strategies that reduce risk to laboratory and clinical staff during 
specimen collection and handling. The capacity to undertake clinical accuracy trials during outbreaks 
should be incorporated into ongoing surveillance activities and protocols written and pre-approved 
by ethics committees and regulators and pre-approved funding secured, to enable timely 












PCR-based molecular diagnostics for Ebolavirus currently dominate, but there have been massive 
advances in biosensor technology in the last decade and we feel the very nature of Ebola lends itself 
to the development of these sequence-independent technologies. The analytical sensitivity of 
molecular diagnostics for Ebolavirus and other known emerging pathogens needs to be determined 
by independent laboratories, using quality controlled and quality assured protocols and reagents, 
provided by some central authority (eg, CDC, or the European BSL-4 network). Ideally, the standards 
or controls used should be non-infectious, such as in-vitro transcripts (IVTs) or non-infectious 
pseudoviruses, to enable testing without the need for BSL-4 containment. Government BSL-4 labs 
should then prioritise the best-performing assays, for evaluations using more clinically relevant 
standards, such as blood spiked with live virus. Development and optimization of POC tests, whether 
RDTs or field-PCR devices should be the focus, but emerging infectious disease diagnostics should 
always be handled by health professionals and public health authorities, who can provide 
confirmatory testing and guide/ensure isolation and treatment of positive cases. In the next five 
years, we would like to see several head-to-head clinical diagnostic evaluations undertaken using 
existing biobanks, or those collected from future outbreaks. These studies need to be carefully 
designed and planned, be considerate to the rights of the patients and the safety of healthcare 
workers. Funding must be secured and ethics approval must be granted by the appropriate ethics 
institutions in all equatorial African countries. Such an endeavour should be led by Africa CDC and 
research groups who are best placed in terms of experience and their close ties with the relevant 
government institutions should be selected in all countries. In 2018 DRC has suffered back-to-back 
EVD outbreaks from independent sources and we anticipate more outbreaks, caused by Ebola 
and/or other novel viruses, as both animal and human populations compete for space and resources 
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Table 1: RT-qPCR tests for the detection of Ebola and other filoviruses 
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Commercial Assays         
RealStar® Filovirus 
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[32].EBOV RNA: 1250 [44] 
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EBOV spiked WB 82 [47]  
EBOV Virus: 0.13 PFU/ml 
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ZEN-TM WB6000 TCID50/ml 
U6000 TCID50/ml 
400 TCID50/ml [129] 




Ebola Virus VP40 




NR WB600 TCID50/ml 
U600 TCID50/ml 
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For ease of legibility all percentages are rounded to the nearest whole number and confidence limits have been excluded. See links to referenced articles if 
more detailed data are required.   
EUA – FDA Emergency Use Authorization. WB (Whole blood), fpWB (finger prick whole blood), Sa (Saliva), Se (Semen), U (Urine), TC spnts (Tissue culture 
supernatants). Number pre-fix specimen type indicates number of specimens. IVT – in vitro transcripts, TCID50 (Tissue culture infectious dose 50), PFU 
(plaque forming units),  
Chemistries: TM = Taqman, LAMP = Loop mediated isothermal amplification, RPA – Recombinase polymerase amplification, ZEN-TM (Taqman using double-
quenching to reduce background signal and increase sensitivity, TM-MGB = Taqman Major Groove binder. 
PCR Platforms: Mx = Mx 3005P™ QPCR System (Stratagene), VS = Versant® kPCR Molecular System AD (Siemens), ABI = ABI Prism® 7500 SDS OR 7500 Fast 












Rotor-Gene Q 5/6 plex Platform (QIAGEN), CX = CFX96 system/Dx real-time system (Bio-Rad), IQ5 = IQ5, BioRad, GE3 = Genie III (OptiGene), LA2 = LA-200 
(Eiken), EXI = ExiStation™ Universal Molecular Diagnostic System or Exicycler™ 96, SLA – SLAN-96P (Shanghai Hongshi Medical Technology) 
RNA extraction kits: QIA = QIAamp® Viral RNA Mini Kit (QIAGEN) , QIS = QIAsymphony® (QIAGEN), NUC = NucliSENS® easyMag® (bioMérieux), MAG = 
MagNA Pure 96 System (Roche), ABB = m2000sp (Abbott) , MAX = Maxwell® 16 IVD Instrument (Promega), VRS = VERSANT® kPCR Molecular System SP 
(Siemens Healthcare), DYN = Dynal BeadRetriever™ System, REY = RNeasy Mini Kit (QIAGEN), EZ1 = EZ1 Virus Mini Kit V 2.0 (QIAGEN), ROC = High Pure Viral 
Nucleic Acid Kit (Roche), AMB = Ambion MagMAX™ Viral RNA Isolation Kit (Ambion, Austin, TX), PCH = Phenol/Chloroform in house method.  
Inclusion of primer and probe sequences was beyond the scope of this paper, but where they are available, see linked reference. See [99] for detailed 
analysis of known mutations in different ebola virus genes. 
 
Table 2: Rapid Diagnostic Tests (RDTs) for the detection of Ebola and other filoviruses 
 
Test Name Manufacturer Target 95% LOD Turnaround Time (Min) 
Storage 
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iSENSE University College London 
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BDBV IgG NR 40 minutes NR None Venous Blood 
 
 
